Viewing nowCombinationTelmisartan Rosuvastatin Tablets 80/5 mg
Telmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Myeongmoon Pharmaceutical Co., Ltd.

MFDS item code 202001845 · Approved 2020.03.17 · Insurance code 649807590
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular disease risk
This medication is used for patients who require the combined administration of telmisartan and rosuvastatin. Telmisartan is primarily effective for patients with essential hypertension, particularly in reducing the risk of myocardial infarction, stroke, and death due to cardiovascular disease in patients aged over 55 who are at high risk for cardiovascular diseases. Rosuvastatin is used for hypercholesterolemia and mixed hyperlipidemia and is prescribed as an adjunct when dietary changes or exercise are insufficient. It is also effective in lowering cholesterol levels in patients with hypercholesterolemia, thereby delaying the progression of atherosclerosis and reducing the risk of cardiovascular events such as stroke and myocardial infarction. By using these two medications together, both blood pressure and cholesterol management are achieved, improving cardiovascular health.
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each ingredient, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg orally once daily as telmisartan; depending on the patient, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. This medicine has an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is generally achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
This medication poses a serious risk of harm or death, particularly to the fetus and newborn, during pregnancy. Therefore, if pregnancy is confirmed, administration should be stopped immediately. Pregnant women, those who may become pregnant, and nursing mothers should not take this medication, and women of childbearing age should use appropriate contraceptive methods. Patients with severely impaired liver or kidney function, certain genetic disorders, or a history of muscle disorders should not use this medication. Elderly patients, those with hyperkalemia, liver impairment, or cardiovascular conditions should be cautious and should take the medication strictly as directed by their physician. This medication may cause muscle-related adverse reactions such as muscle pain, myopathy, and rhabdomyolysis; therefore, if muscle ache or weakness occurs, patients should consult with their doctor immediately. There is a risk of liver function abnormalities, so liver function tests should be periodically performed before and during treatment. There is a potential for blood pressure to drop too low, which may cause dizziness or fainting; if symptoms occur, patients should notify healthcare professionals. This medication may interact with other drugs, so if there are any other medications being taken, it is essential to inform the doctor or pharmacist. In case of overdose, symptoms such as hypotension, dizziness, and acute renal failure may occur, and patients should seek medical attention immediately. Care should be taken while driving or operating machinery as dizziness or drowsiness may occur.
Headache, postural dizziness, sleep paralysis, blood pressure increase, blood pressure decrease, hypotension, ALT elevation, dysuria, rhinitis, discomfort in oropharynx, pulmonary disease, unspecified intestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorder, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, shortness of breath, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, liver dysfunction, hepatic impairment, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, dermatitis, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, muscular weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, hypoglycemia, angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, cough, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, palpitations, fatigue, nausea, insufficient effect, cough, myalgia, dermatitis, increased ALT, increased CK, constipation, increased AST, numbness, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, muscle cramps, gout
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. Additionally, it should be kept at room temperature between 1 and 30 degrees Celsius, avoiding extremes of heat or cold.
Bright pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP*3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationTelmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Myeongmoon Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhannanghang Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhan Corporation Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.